Association between Duration of Visual Symptoms and Early Postoperative Visual Outcome Following Pituitary Macroadenoma Surgery.

Pituitary tumors represent approximately 10.0-17.0% of intracranial tumors. However, they may grow large and extend into surrounding structures, resulting in neurological and hormonal complications, including visual impairment. The duration of visual involvement will help predict visual outcomes after pituitary surgery and will be helpful for patient counseling. This prospective observational study was conducted in the neurosurgery department of Bangabandhu Sheikh Mujib Medical University (BSMMU), Bangladesh. The patient who fulfilled the selection criteria which included (specific criteria) was enrolled in this study and was divided into two groups according to the Duration of visual symptoms. A total of 24 patients were selected; 12 presented with visual symptoms with less than six months duration; they were included in the first group and 12 patients with more than 6 months duration were included in the second group. Patient data were recorded in a predetermined data sheet. An ophthalmologist examined visual status. Data was processed and analyzed using SPSS version 22.0. An appropriate statistical test for data analysis (Chi-square test and student t-test) was performed. Statistical significance was at p-value <0.05 at a 95% confidence interval level. The age distribution of 24 patients ranged from 17-64 years, with a mean ±SD of age of 36.21±13.7. Males had slightly more preponderance than females in this series, with a male-to-female ratio 1.2:1. All patients presented with visual problems (100.0%). The majority (93.3%) patients presented with headache, 6 patients (25.0%) presented with acromegaly, 1 patient (4.2%) presented with hypothyroid and 3 patients (12.5%) presented with amenorrhea and galactorrhea. Regarding visual acuity symptoms less than 6 months, 58.3% were improved, and 41.7% were not improved. Visual symptoms of more than 6 months duration 25.0% out of 24 eyes improved and 18(75.0%) did not improve post-operatively; we found that visual symptoms of less than 6 months improved better postoperatively (p-value 0.001). This study reveals a significant association between the duration of preoperative visual symptoms and early postoperative visual outcomes in patients with pituitary macroadenoma surgery. Specifically, patients presenting with less than 6 months of visual symptoms showed a marked improvement compared to those with more than six months duration. These findings provide valuable insights for patient counseling and early intervention strategies.